Faculty Opinions recommendation of Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.

Faculty Opinions recommendation of Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726165826.793550720 ◽

2018 ◽

Author(s):

WH Wilson Tang

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Cancer Therapy ◽

Cardiac Dysfunction ◽

Breast Cancer Therapy ◽

Double Blind ◽

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

European Heart Journal ◽

10.1093/eurheartj/ehw022 ◽

2016 ◽

Vol 37 (21) ◽

pp. 1671-1680 ◽

Cited By ~ 274

Author(s):

Geeta Gulati ◽

Siri Lagethon Heck ◽

Anne Hansen Ree ◽

Pavel Hoffmann ◽

Jeanette Schulz-Menger ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Cancer Therapy ◽

Cardiac Dysfunction ◽

Breast Cancer Therapy ◽

Double Blind ◽

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol

Circulation ◽

10.1161/circulationaha.121.054698 ◽

2021 ◽

Author(s):

Siri Lagethon Heck ◽

Albulena Mecinaj ◽

Anne Hansen Ree ◽

Pavel Hoffmann ◽

Jeanette Esther Schulz-Menger ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Cancer Therapy ◽

Cardiac Dysfunction ◽

Breast Cancer Therapy ◽

Double Blind ◽

Faculty Opinions recommendation of Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726165826.793555465 ◽

2019 ◽

Author(s):

Maurie Markman

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Cancer Therapy ◽

Cardiac Dysfunction ◽

Breast Cancer Therapy ◽

Double Blind ◽

Decreased Use of Adjuvant Breast Cancer Therapy in a Randomized Controlled Trial of a Decision Aid with Individualized Risk Information

Medical Decision Making ◽

10.1177/0272989x05276851 ◽

2005 ◽

Vol 25 (3) ◽

pp. 301-307 ◽

Cited By ~ 67

Author(s):

Pamela B. Peele ◽

Laura A. Siminoff ◽

Ying Xu ◽

Peter M. Ravdin

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trial ◽

Cancer Therapy ◽

Decision Aid ◽

Controlled Trial ◽

Risk Information ◽

Breast Cancer Therapy ◽

Randomized Controlled ◽

Efficacy of pamidronate on skeletal complications from breast cancer metastases. A prospective randomized double-blind placebo-controlled trial

Bone ◽

10.1016/8756-3282(96)88003-3 ◽

1995 ◽

Vol 17 (6) ◽

pp. 613

Author(s):

R. Hultborn ◽

S. Rydén ◽

S. Gundersen ◽

E. Holmberg ◽

U.-B. Wallgren

Keyword(s):

Breast Cancer ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Breast Cancer Metastases ◽

Cancer Metastases ◽

Skeletal Complications

Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial

Yearbook of Medicine ◽

10.1016/s0084-3873(12)00185-x ◽

2012 ◽

Vol 2012 ◽

pp. 115-116

Author(s):

C. Lawton

Keyword(s):

Breast Cancer ◽

Controlled Trial ◽

Hot Flashes ◽

Double Blind ◽

Double Blind Placebo

Effects of Goshajinkigan (TJ-107) for oxaliplatin-induced peripheral neurotoxicity using the functional assessment of cancer therapy/gynecologic oncology group 12-item neurotoxicity questionnaire in a Phase II, multicenter, randomized, double-blind, placebo-controlled trial

Journal of Cancer Research and Therapeutics ◽

10.4103/jcrt.jcrt_1123_19 ◽

2020 ◽

Vol 0 (0) ◽

pp. 0

Author(s):

Toru Aoyama ◽

Satoshi Morita ◽

Toru Kono ◽

Taishi Hata ◽

Hideyuki Mishima ◽

...

Keyword(s):

Cancer Therapy ◽

Functional Assessment ◽

Controlled Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peripheral Neurotoxicity ◽

Double Blind ◽

Double Blind Placebo ◽

Group 12

The Evolving Role of Aromatase Inhibitors in Adjuvant Breast Cancer Therapy

Clinical Breast Cancer ◽

10.3816/cbc.2005.n.022 ◽

2005 ◽

Vol 6 (3) ◽

pp. 206-215 ◽

Cited By ~ 4

Author(s):

I. Craig Henderson ◽

Martine J. Piccart-Gebhart

Keyword(s):

Breast Cancer ◽

Cancer Therapy ◽

Aromatase Inhibitors ◽

Breast Cancer Therapy ◽

Adjuvant breast cancer therapy - disease-free vs overall survival

Inpharma Weekly ◽

10.2165/00128413-199409250-00007 ◽

1994 ◽

Vol &NA; (925) ◽

pp. 5

Author(s):

&NA;

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Cancer Therapy ◽

Breast Cancer Therapy ◽

Adjuvant Breast Cancer ◽

Disease Free